Clinical trials: Borderline-resectable Pancreatic Cancer
Pancreatic Cancer
Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer
There is no a clear consensus regarding the optimal treatment of locally advanced pancreatic disease. There is a potential role for neoadjuvant therapy to treat micrometastatic disease with chemotherapy, as well as for the…
- Trial name
- NCT02984501
- Testing
- Radiation, Chemotherapy
- Volunteers
- 41 people
- Sponsor
- Campus Bio-Medico University
Pancreatic Neoplasm, Pancreatic Adenocarcinoma
Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Surgical resection is the only potentially curative treatment for patients with pancreatic cancer with the aim of curative R0 resection and related improvement of survival.
- Conditions
- Pancreatic Neoplasm, Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
- Trial name
- STEREOPAC (NCT05083247)
- Testing
- mFOLFIRINOX or Gemcitabine nab-paclitaxel, Isotoxic High-Dose (iHD)-SBRT, Surgery
- Where
- 10 sites in Belgium
- Volunteers
- 256 people
- Sponsor
- Erasme University Hospital
SBRT, Borderline Resectable Pancreatic Cancer
Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline…
- Conditions
- SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
- Trial name
- NCT04698915
- Testing
- Drug GC4711
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 177 people
- Sponsor
- Galera Therapeutics, Inc.
Pancreas Cancer
Surgical Results of Resection of Locally Advanced Pancreatic Cancer
The aim is to compare the surgical outcomes between upfront surgery and surgery after neoadjuvant chemotherapy in terms of morbidity and mortality
- Trial name
- NCT06206382
- Testing
- Whipple operation
- Volunteers
- 80 people
- Sponsor
- Assiut University
Pancreatic Ductal Adenocarcinoma
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
This is an open-label phase 1/2 study that will combine the chemotherapy agents gemcitabine and nab-paclitaxel with an oral hedgehog inhibitor LDE225 (Sonidegib).
- Trial name
- NCT01431794
- Testing
- LDE225-600mg, Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Pancreatic Adenocarcinoma
Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol
The combination of capecitabine, oxaliplatin, and irinotecan (CAPOXIRI) may be better than other combinations used to treat earlier stage pancreatic cancer patients with resectable (able to be cut out), borderline resectable, and…
- Trial name
- NCT01760252
- Testing
- Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Beth Israel Medical Center